285 related articles for article (PubMed ID: 21943380)
1. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
[TBL] [Abstract][Full Text] [Related]
2. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
4. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
[TBL] [Abstract][Full Text] [Related]
7. Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.
Xu X; Chang X; Li Z; Wang J; Deng P; Zhu X; Liu J; Zhang C; Chen S; Dai D
Cell Oncol (Dordr); 2015 Jun; 38(3):183-94. PubMed ID: 25801783
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.
Nordström L; Andersson E; Kuci V; Gustavsson E; Holm K; Ringnér M; Guldberg P; Ek S
BMC Cancer; 2015 Apr; 15():273. PubMed ID: 25880212
[TBL] [Abstract][Full Text] [Related]
9. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
10. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer.
Brennan DJ; Ek S; Doyle E; Drew T; Foley M; Flannelly G; O'Connor DP; Gallagher WM; Kilpinen S; Kallioniemi OP; Jirstrom K; O'Herlihy C; Borrebaeck CA
Eur J Cancer; 2009 May; 45(8):1510-7. PubMed ID: 19272768
[TBL] [Abstract][Full Text] [Related]
11. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
12. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
Peng DX; Luo M; Qiu LW; He YL; Wang XF
Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
15. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
16. The Role of Abnormal Methylation of Wnt5a Gene Promoter Regions in Human Epithelial Ovarian Cancer: A Clinical and Experimental Study.
Jin P; Song Y; Yu G
Anal Cell Pathol (Amst); 2018; 2018():6567081. PubMed ID: 30079293
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract][Full Text] [Related]
18. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer.
Pattamadilok J; Huapai N; Rattanatanyong P; Vasurattana A; Triratanachat S; Tresukosol D; Mutirangura A
Int J Gynecol Cancer; 2008; 18(4):711-7. PubMed ID: 17944913
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
[TBL] [Abstract][Full Text] [Related]
20. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]